gptkbp:instance_of
|
gptkb:vaccine
|
gptkbp:average_temperature
|
-20° C to -80° C
|
gptkbp:clinical_trial
|
tens of thousands
multiple countries
Phase 3
|
gptkbp:collaborated_with
|
gptkb:Moderna
|
gptkbp:community_health
|
gptkb:significant
|
gptkbp:developed_by
|
gptkb:Roche
|
gptkbp:dosage_form
|
yes
two doses
|
gptkbp:effective_date
|
2021-12-01
|
gptkbp:funding
|
government and private sectors
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche's COVID-19 vaccine
|
gptkbp:is_effective_against
|
approximately 95%
|
gptkbp:is_vulnerable_to
|
gptkb:virus
gptkb:logistics
worldwide
high
ongoing
government grants
international organizations
public awareness campaigns
priority
safety and efficacy
rapid
phased approach
essential
equitable
lipid nanoparticle
community immunity
against severe disease
against hospitalization
against symptomatic infection
m RNA technology
limited in early stages
|
gptkbp:market
|
ongoing
|
gptkbp:marketed_as
|
gptkb:brand
|
gptkbp:production_location
|
gptkb:Switzerland
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:WHO
gptkb:EMA
|
gptkbp:route_of_administration
|
intramuscular injection
|
gptkbp:safety_features
|
well-studied
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
injection site pain
|
gptkbp:supply_chain
|
global
|
gptkbp:target_audience
|
adults
children over 12
|
gptkbp:targets
|
gptkb:COVID-19
|
gptkbp:type
|
gptkb:vaccine
|
gptkbp:vaccine_approval_process
|
expedited
|
gptkbp:vaccine_collaboration
|
pharmaceutical companies
|
gptkbp:vaccine_distribution_network
|
established
|
gptkbp:vaccine_health_equity
|
focus area
|
gptkbp:vaccine_impact_assessment
|
ongoing research
|
gptkbp:vaccine_public_health_policy
|
influential
|
gptkbp:vaccine_public_health_strategy
|
containment of COVID-19
|
gptkbp:vaccine_public_trust
|
critical for uptake
|
gptkbp:vaccine_regulatory_compliance
|
stringent
|
gptkbp:vaccine_research_focus
|
variants of concern
|
gptkbp:bfsParent
|
gptkb:Lonza_Group
|
gptkbp:bfsLayer
|
6
|